Gadoteridol

ProHance Wins Technology of the Year Runner-Up at the 2024 North American SSON Impact Awards

Retrieved on: 
Thursday, April 4, 2024
Automation, Organization, Growth, Screencast, Time management, Software, Gadoteridol, Asset, Workforce, Shared services, Work Time, Renewable energy

ORLANDO, Fla., April 4, 2024 /PRNewswire/ -- ProHance , a leading workforce analytics and operations enablement platform was chosen for the prestigious 2024 North American SSON Impact Awards as the runner-up for 'Technology of the Year Impact Award' during the Shared Services & Outsourcing Network (SSON) held in Orlando.

Key Points: 
  • ORLANDO, Fla., April 4, 2024 /PRNewswire/ -- ProHance , a leading workforce analytics and operations enablement platform was chosen for the prestigious 2024 North American SSON Impact Awards as the runner-up for 'Technology of the Year Impact Award' during the Shared Services & Outsourcing Network (SSON) held in Orlando.
  • ProHance's technology platform enables organizations to gain actionable insights into their operations, optimize workforce productivity, streamline processes, and enhance decision-making capabilities.
  • By leveraging advanced analytics, automation, and real-time monitoring, ProHance empowers organizations to achieve operational excellence and drive sustainable growth.
  • ProHance remains committed to driving innovation, delivering exceptional value, and empowering organizations to thrive in an increasingly competitive and dynamic business landscape.

ProHance Announces Investment from Chrys Capital

Retrieved on: 
Thursday, December 7, 2023
BLC, BFSI, Acquisition, Software as a service, Gadoteridol, GCC, Management

Bangalore, India November 30, 2023: ProHance , a new-age workplace analytics and operations management platform company announced today a majority investment from ChrysCapital.

Key Points: 
  • Bangalore, India November 30, 2023: ProHance , a new-age workplace analytics and operations management platform company announced today a majority investment from ChrysCapital.
  • The investment will be primarily used to accelerate ProHance’s expansion across the globe and further strengthen its market dominance.
  • ProHance was founded by Kishore Reddy and Rajesh Sharma in 2009 with a vision of creating a world class global product out of India.
  • The investment marks ChrysCapital’s foray into the growing Indian SaaS ecosystem valued at over $12 billion.

ProHance Achieves SOC 2 Type 2 Certification; distinguishes itself as a trusted and reliable partner in the SaaS industry

Retrieved on: 
Thursday, July 6, 2023
Software as a service, Service, Disclosure, Privacy, SOC, Confidentiality, AICPA, Certification, Organization, Type 2, SOC 2, American Institute, Gadoteridol, Audit

ProHance attains SOC 2 Type 2 Certification; distinguishes itself as a trusted and reliable partner in the SaaS industry

Key Points: 
  • ProHance attains SOC 2 Type 2 Certification; distinguishes itself as a trusted and reliable partner in the SaaS industry
    SOC 2 (Service Organization Control 2) is an internationally recognized auditing standard developed by the American Institute of CPAs (AICPA).
  • It focuses on evaluating the controls and safeguards implemented by service organizations to protect customer data.
  • The Type 2 certification requires an extended audit period, typically six months or longer, to assess the effectiveness of these controls over time.
  • The certification establishes ProHance as a trusted and reliable partner in the SaaS industry, providing organizations with the assurance that their data is protected and handled with vigilance.

ProHance Analytics Sponsors HFMA Annual Conference 2023 in Nashville

Retrieved on: 
Friday, June 23, 2023
Workforce, Senior, Health, Health care, RCM, Booth, Healthcare Financial Management Association, HFMA, Gadoteridol, Conference, Gaylord Opryland Resort & Convention Center

NASHVILLE, Tenn., June 23, 2023 /PRNewswire/ -- ProHance Analytics , a leading new-age workplace analytics and operations enablement platform, is pleased to announce its sponsorship of the HFMA Annual Conference 2023.

Key Points: 
  • NASHVILLE, Tenn., June 23, 2023 /PRNewswire/ -- ProHance Analytics , a leading new-age workplace analytics and operations enablement platform, is pleased to announce its sponsorship of the HFMA Annual Conference 2023.
  • Organized by the Healthcare Financial Management Association (HFMA), the conference is scheduled to take place from June 25th to 28th at Gaylord Opryland in Nashville, Tennessee.
  • During the conference, ProHance Analytics will showcase its cutting-edge solutions designed to address the evolving needs of healthcare finance professionals.
  • ProHance Analytics senior leadership team - Kishore Reddy and Khiv Singh - will be present at Booth 1149 during the conference to connect with healthcare leaders.

Dissolution of Bracco-Eisai Joint Venture

Retrieved on: 
Tuesday, February 21, 2023
Partnership, System Technology-i Co, Ltd, MRI, Patient, Google Images, Iomeprol, Environment, Gadoteridol, Medical imaging, Eisai

TOKYO, Feb 21, 2023 - (JCN Newswire) - Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023.

Key Points: 
  • TOKYO, Feb 21, 2023 - (JCN Newswire) - Bracco Imaging S.p.A. and Eisai Co., Ltd. announced today that the joint venture regarding the company Bracco-Eisai Co., Ltd. (Ratio of Shares Held: Bracco 51% Eisai 49%), will be dissolved as of March 31, 2023.
  • As a result, Bracco will acquire all shares of Bracco-Eisai held by Eisai and change its name from Bracco-Eisai to Bracco Japan, Co., Ltd. as of April 1, 2023.
  • Bracco and Eisai established Bracco-Eisai in 1990 with the aim of establishing a contrast agent business in Japan.
  • After comprehensive consideration, the companies decided to dissolve the joint venture in order to respond quickly and flexibly to the changing environment surrounding the healthcare industry and achieve sustainable contributions to patients through these products.

ProHance Analytics Officially Launches in the US Hybrid Work Software Market

Retrieved on: 
Friday, December 16, 2022
Omni, Privacy, Software, Growth, Workforce, Gadoteridol, Software as a service, Omnichannel, Trial balance, Risk management, Management

The announcement is part of their development strategy in the wake of hybrid work software.

Key Points: 
  • The announcement is part of their development strategy in the wake of hybrid work software.
  • The hybrid work model has transformed the way businesses and employees operate all around the world.
  • Access to effective tools and software for workforce management and productivity, on the other hand, is critical for making hybrid work efficient and productive.
  • The visibility and actionable analytics provided by ProHance Analytics help Enterprises make their operations more customer-centric, efficient, and lean.

Voluntary dismissal of Norris case

Retrieved on: 
Thursday, January 16, 2020
Chemistry, Bracco, Gadobenic acid, Norris, Magnetic resonance imaging, Gadoteridol, Magnetic resonance, Physical sciences, Chemical substances

However, Bracco is pleased to announce today that thelawsuit filed by Chuck and Gena Norris, in which Mrs. Norris alleged injury from Bracco's magnetic resonance (MR) contrast agent MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, has been voluntarily dismissed by Mr. and Mrs. Norris.

Key Points: 
  • However, Bracco is pleased to announce today that thelawsuit filed by Chuck and Gena Norris, in which Mrs. Norris alleged injury from Bracco's magnetic resonance (MR) contrast agent MultiHance (gadobenate dimeglumine) injection, 529 mg/mL, has been voluntarily dismissed by Mr. and Mrs. Norris.
  • The decision to dismiss the lawsuit was entirely that of Mr. and Mrs. Norris and their attorneys.
  • For further information, please refer to the Bracco November 2, 2017 press release at https://imaging.bracco.com/us-en .
  • ProHance (Gadoteridol) Injection, 279.3 mg/mL is indicated for use in MRI in adults to visualize lesions in the head and neck.

Artificial intelligence software confirms the results of a large scale comparison of ProHance® (Gadoteridol) Injection, 279.3 mg/mL and Gadavist® (gadobutrol) Injection in MRI of the brain (the TRUTH study)

Retrieved on: 
Tuesday, December 3, 2019
Covariance and correlation, Gadobutrol, Pearson correlation coefficient, Correlation and dependence, Gadoteridol, Correlation coefficient, Enhancement, Research methods, Scientific method, Analysis

Each of the 32 patients with GBM in the study received both ProHance contrast and Gadavist contrast in a double-blind, randomized crossover technique.

Key Points: 
  • Each of the 32 patients with GBM in the study received both ProHance contrast and Gadavist contrast in a double-blind, randomized crossover technique.
  • * Enhancement characteristics for both agents were processed and the differences for each set of image pairs were calculated and analyzed.
  • The Pearson correlation coefficient between the normalized ProHance contrast and Gadavist contrast was 0.958 (p
  • ProHance (Gadoteridol) Injection, 279.3 mg/mL is indicated for use in MRI in adults to visualize lesions in the head and neck.